A Single-center, Open-label, Study Evaluating Safety and Pharmacokinetics of Single Doses of Zidebactam-Cefepime and Metronidazole Alone or in Combination.
Phase 1
Recruiting
- Conditions
- PHA1A
- Interventions
- First Posted Date
- 2025-02-04
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Wockhardt
- Target Recruit Count
- 30
- Registration Number
- NCT06806995
- Locations
- πΊπΈ
Advanced Pharma CR, LLC, Miami, Florida, United States
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intravenous WCK 771
Phase 1
Completed
- Conditions
- Bioavailability
- Interventions
- Drug: WCK 771 IV InfusionOther: Placebo IV Infusion
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2022-12-07
- Lead Sponsor
- Wockhardt
- Target Recruit Count
- 36
- Registration Number
- NCT05640531
- Locations
- πΊπΈ
PPD Phase I Clinic, 7551 Metro Center Drive, Suite 200, Austin, Texas, United States
Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
Phase 3
Completed
- Conditions
- Complicated Urinary Tract InfectionAcute Pyelonephritis
- Interventions
- Drug: Cefepime-zidebactam (FEP-ZID)
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Wockhardt
- Target Recruit Count
- 530
- Registration Number
- NCT04979806
- Locations
- π§π¬
Multiprofile Hospital for Active Teatment (MHAT) and Emergency Medicine - Pirogov, Sofia, Bulgaria
π²π½Centro de Investigacion Clinica de Oaxaca (CICLO), Oaxaca, Mexico
π²π½Pharmacology & Clinical Research, Queretaro Qro, Mexico
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Oral WCK 2349
Phase 1
Completed
- Conditions
- Pharmacokinetics
- Interventions
- Drug: WCK 2349 OralOther: Placebo Oral
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2022-12-01
- Lead Sponsor
- Wockhardt
- Target Recruit Count
- 36
- Registration Number
- NCT04874324
Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Intravenous Nafithromycin
- First Posted Date
- 2019-06-11
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- Wockhardt
- Target Recruit Count
- 10
- Registration Number
- NCT03981887
- Locations
- πΊπΈ
Spaulding Clinical Research, West Bend, Wisconsin, United States
Evaluate The Safety, Tolerability and Pharmacokinetics Of Multiple Ascending Oral Doses Of WCK 4873 In Healthy Adult Volunteers
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2019-06-11
- Lead Sponsor
- Wockhardt
- Target Recruit Count
- 30
- Registration Number
- NCT03979859
The Safety, Tolerability And Pharmacokinetics Of Single Ascending Doses And The Effect Of Food On Oral WCK 4873 In Healthy Adult Volunteers
- First Posted Date
- 2019-04-25
- Last Posted Date
- 2019-04-25
- Lead Sponsor
- Wockhardt
- Target Recruit Count
- 67
- Registration Number
- NCT03926962
Plasma and Intrapulmonary Concentrations Study of WCK 5222
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2018-08-14
- Lead Sponsor
- Wockhardt
- Target Recruit Count
- 36
- Registration Number
- NCT03630094
- Locations
- πΊπΈ
Pulmonary Associates, Phoenix, Arizona, United States
Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
Phase 3
Not yet recruiting
- Conditions
- Complicated Urinary Tract InfectionAcute Pyelonephritis
- Interventions
- Drug: WCK 4282 (FEP-TAZ) 4 gOther: Infusion of normal saline
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- Wockhardt
- Target Recruit Count
- 1004
- Registration Number
- NCT03630081
To Investigate the Multiple Dose Safety, Tolerability and Pharmacokinetics of WCK 4282 (FEP-TAZ)
Phase 1
Completed
- Conditions
- Antibiotics Causing Adverse Effects in Therapeutic Use
- Interventions
- Other: PlaceboDrug: FEP-TAZ 4 g
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2018-08-10
- Lead Sponsor
- Wockhardt
- Target Recruit Count
- 20
- Registration Number
- NCT03622008
- Locations
- πΊπΈ
Spaulding Clinical Research, West Bend, Wisconsin, United States
Β© Copyright 2025. All Rights Reserved by MedPath